| Endocrine Gland Neoplasms |
POET, NCT03014687: Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions |
|
|
| Recruiting | 4 | 116 | US | Placebo, inert substance, Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole, Omnicef, Bactrim DSâ„¢ cephalosporin intolerant patients | St. Joseph's Hospital and Medical Center, Phoenix, Thomas Jefferson University, The Cleveland Clinic | Antibiotics, Pituitary Adenoma | 01/19 | 07/19 | | |
SANO, NCT02705651: Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment |
|
|
| Not yet recruiting | 3 | 180 | NA | Somatostatin-Analog | Medical University of Vienna | Pancreatic Neuroendocrine Tumors in MEN1 | 10/23 | 10/24 | | |
NCT02159820: Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer |
|
|
| Recruiting | 2/3 | 500 | RoW | Decitabine (DTC Arm), Paclitaxel and Carboplatin (TC Arm) | Chinese PLA General Hospital | Primary Malignant Neoplasm of Ovary, FIGO Stages II to IV | 06/24 | 06/24 | | |
NCT01786850: Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer |
|
|
| Available | 2 | | Europe | Magnetic Resonance-guided High-intensity Focused Ultrasound (MRgFUS) | University of Roma La Sapienza | Pancreas, Cancer, Locally Advanced Pancreatic Cancer, Non-invasive Treatment | | | | |
NCT00962520: Tarceva With Chemoradiation and Adjuvant Chemotherapy for Resectable Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 40 | US | Erlotinib, Tarceva, capecitabine, Xeloda, Radiation Therapy, gemcitabine, Gemzar, erlotinib | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Genentech, Inc. | Pancreatic Cancer | 04/22 | 04/23 | | |
|
|
OCCLURANDOM, NCT02230176: Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II |
|
|
| Recruiting | 2 | 80 | Europe | Sunitinib, 177Lu-DOTA0-Tyr3-Octreotate | Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France, Advanced Accelerator Applications | Pancreatic Neuroendocrine Carcinoma | 10/23 | 10/23 | | |
NCT02487693: Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma |
|
|
| Active, not recruiting | 2 | 50 | RoW | Radiofrequency ablation, RFA, Cytokine-induced killer cells, CIK | The First People's Hospital of Changzhou | Ovarian Carcinoma | 06/38 | 06/40 | | |
NCT02090127: Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient |
|
|
| No Longer Available | N/A | | US | ficlatuzumab, AV-299, SCH 900105 | AVEO Pharmaceuticals, Inc. | Mullerian Mixed Tumor of Ovary | | | | |
NCT02937467: The Multi-Center Study of Shear Wave Elastography on Thyroid Nodules |
|
|
| Available | N/A | | RoW | SWE | Peking University Cancer Hospital & Institute, Shanghai 10th People's Hospital | Thyroid Nodules | 12/17 | 12/18 | | |
NCT03063710: Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan |
|
|
| No Longer Available | N/A | | Japan | olaparib | AstraZeneca | PSR Ovarian Cancer With a BRCA Mutation | | | | |
NCT02686463: Treatment for Malignant Ovarian Cancer: Laparoscopy vs Laparotomy |
|
|
| Not yet recruiting | N/A | 150 | RoW | Laparoscopy, Laparotomy | Shengjing Hospital | Ovarian Cancer | 06/18 | 06/23 | | |
NCT03006939: Fluid Balance During Surgery for Ovarian Cancer |
|
|
| Recruiting | N/A | 60 | Europe | Cytoreductive surgery | University Hospital, Bonn | Ovarian Neoplasm, Fluid Therapy | 12/19 | 12/22 | | |
NCT01382420: Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma |
|
|
| Recruiting | N/A | 234 | RoW | surgery | Samsung Medical Center, Asan Medical Center, Severance Hospital, Konkuk University Medical Center | Cushing Syndrome | 05/20 | 05/24 | | |
NCT02869568: Institut Paoli Calmettes Ovarian Cancer Database |
|
|
| Recruiting | N/A | 6000 | Europe | Data collection | Institut Paoli-Calmettes | Ovarian Neoplasms | 01/30 | 12/30 | | |
NCT02869581: Institut Paoli-Calmettes Pancreatic Neoplasms Database |
|
|
| Recruiting | N/A | 8500 | Europe | Data collection | Institut Paoli-Calmettes | Pancreatic Neoplasms | 01/30 | 12/30 | | |
NCT02869620: Institut Paoli Calmettes Thyroid Cancer Database |
|
|
| Recruiting | N/A | 3000 | Europe | Data collection | Institut Paoli-Calmettes | Thyroid Neoplasms | 01/30 | 12/30 | | |
| Recruiting | N/A | 1500 | Europe | Data collection | Institut Paoli-Calmettes | Pancreatic Neoplasms | 11/30 | | | |
| Recruiting | N/A | 3000 | RoW | | Kangbuk Samsung Hospital | Ovarian Neoplasms | 12/40 | 12/40 | | |
NCT01000259: Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer |
|
|
| Recruiting | N/A | 174 | US | Laboratory Biomarker Analysis | Gynecologic Oncology Group, National Cancer Institute (NCI) | Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer | 01/00 | | | |
NCT01445275: Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 |
|
|
| Not yet recruiting | N/A | 2605 | US | Evaluation of Cancer Risk Factors, cancer risk factors evaluation, Medical Chart Review, Chart Review, Study of Socioeconomic and Demographic Variables | Gynecologic Oncology Group, National Cancer Institute (NCI) | Fallopian Tube Carcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Ovarian Carcinoma, Primary Peritoneal Carcinoma | 01/00 | | | |